- Location
1
result for "
Jakavi
"-
Novartis Received The European Commission Approval for Jakavi
Dec 7, 2012Novartis, Incyte's strategic collaborator, has received the European Commission approval for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor to treat patients with myelofibrosis. The oral JAK 1 and JAK 2 inhibitor ...
Related Products
-
Safe Delivery 99% Purity Ruxolitinib / Ruxolitinib Phosphate Powder Door to Door
-
China Factory 99% Pure Ruxolitinib Raw Powder CAS 941678-49-5 Pharmaceutical Grade Safe Delivery
-
USA Europe Singapore etc, 99% Pure Ruxolitinib Raw Powder CAS 941678-49-5 Safe Shipping Door to Door
-
Made in China, 99% Pure Ruxolitinib Phosphate Powder CAS 1092939-17-7 No Customs Issues Door to Door
